ARRIVENT BIOPHARMA, INC. Other Comprehensive Income (Loss), Net of Tax
ARRIVENT BIOPHARMA, INC. (AVBP) reported Other Comprehensive Income (Loss), Net of Tax of $3.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-12
- ARRIVENT BIOPHARMA, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-06-30 was $3.00K.
- ARRIVENT BIOPHARMA, INC. other comprehensive income (loss), net of tax for the quarter ending 2026-03-31 was -$284.00K, a 246.39% decline year-over-year.
- ARRIVENT BIOPHARMA, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-12-31 was -$194.00K.
- ARRIVENT BIOPHARMA, INC. other comprehensive income (loss), net of tax for the quarter ending 2025-09-30 was $226.00K.
- ARRIVENT BIOPHARMA, INC. other comprehensive income (loss), net of tax for fiscal 2025 was $225.00K.
- ARRIVENT BIOPHARMA, INC. other comprehensive income (loss), net of tax for fiscal 2024 was -$211.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.00K 10-Q · filed 2026-08-12 | -$282.00K 10-Q · filed 2026-08-12 | -$475.00K derived: sum of 3 quarters · filed 2026-08-12 | -$249.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$284.00K 10-Q · filed 2026-05-11 | -$478.00K derived: sum of 2 quarters · filed 2026-05-11 | -$252.00K derived: sum of 3 quarters · filed 2026-05-11 | -$253.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$194.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $32.00K derived: sum of 2 quarters · filed 2026-03-05 | $31.00K derived: sum of 3 quarters · filed 2026-08-12 | $225.00K 10-K · filed 2026-03-05 |
| 2025-09-30 | $226.00K 10-Q · filed 2025-11-10 | $225.00K derived: sum of 2 quarters · filed 2026-08-12 | $419.00K 10-Q · filed 2025-11-10 | |
| 2025-06-30 | -$1.00K 10-Q · filed 2026-08-12 | $193.00K 10-Q · filed 2026-08-12 | ||
| 2025-03-31 | $194.00K 10-Q · filed 2026-05-11 | |||
| 2024-12-31 | -$211.00K 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |